Dr. Estela Rodriguez(@Latinamd) 's Twitter Profileg
Dr. Estela Rodriguez

@Latinamd

Associate Director Community Outreach- DEI- 🫁Thoracic Oncology, University of Miami @SylvesterCancer , 🇵🇷Boricua, Co-founder @KidsHelpingKidsSucceed

ID:597647783

linkhttps://linktr.ee/latinamd calendar_today02-06-2012 18:46:57

9,3K Tweets

6,4K Followers

3,1K Following

Follow People
Jacquelyne Gaddy, MD(@JacquelyneGMD) 's Twitter Profile Photo
Jacquelyne Gaddy, MD
@JacquelyneGMD

1 year ago

First commentary as an attending!

Addressing Racial, Ethnic, and Age Disparities in Cancer Clinical Trial Enrollment ja.ma/3U0JWgT via JAMA Oncology part of JAMA Network

account_circle
Ana I. Velázquez Mañana, MD MSc (she/her/ella)(@AnaVManana) 's Twitter Profile Photo
Ana I. Velázquez Mañana, MD MSc (she/her/ella)
@AnaVManana

1 year ago

🔑 Key resource & publication from Ash Alpert Don S. Dizon MD (he/him) 🇬🇺 et al providing a framework for of People in

Relevant to investigators industry & other funders/regulatory agencies
Journal of Clinical Oncology
ascopubs.org/doi/full/10.12…

🔑 Key resource & publication from @ash_alpert @drdonsdizon et al providing a framework for #Inclusion of #Transgender People in #Oncology #clinicalTrials Relevant to #cancercenters investigators industry & other funders/regulatory agencies @JCO_ASCO ascopubs.org/doi/full/10.12…
account_circle
Benjamin Besse(@BenjaminBesseMD) 's Twitter Profile Photo
Benjamin Besse
@BenjaminBesseMD

1 year ago

Resistance to specific RET inhibitors is quite heterogeneous, with only 14% on-target resistance mechanisms. Large study in 100+ patients on primary and secondary resistance. It will not ease the development of 2nd gen inhibitors! Mihaela Aldea Arianna Marinello

Resistance to specific RET inhibitors is quite heterogeneous, with only 14% on-target resistance mechanisms. Large study in 100+ patients on primary and secondary resistance. It will not ease the development of 2nd gen inhibitors! #ENA2022 @mihaela_aldea @AriMarinel
account_circle
IASLC(@IASLC) 's Twitter Profile Photo
IASLC
@IASLC

1 year ago

At Dr. Miyako Satouchi highlights research on chemo for --including the long journey of SCLC treatment development including and forthcoming targeted therapies.

At #ACLC22 Dr. Miyako Satouchi highlights research on chemo for #SCLC--including the long journey of SCLC treatment development including #immunotherapy and forthcoming targeted therapies.
account_circle
Rami Manochakian, MD 🇺🇸🇸🇾 #CancerEducation(@RManochakian) 's Twitter Profile Photo
Rami Manochakian, MD 🇺🇸🇸🇾 #CancerEducation
@RManochakian

1 year ago

🔥🚨Hot off the press Journal of Clinical Oncology & Clinical Cancer Research; Joint policy statement by ASCO & AACR on Electronic Delivery Systems, outlining latest research in this area & recommendations for regulating these products to protect .

OncoAlert
👇🏼
ascopubs.org/doi/full/10.12…

🔥🚨Hot off the press @JCO_ASCO & @CCR_AACR; Joint policy statement by @ASCO & @AACR on Electronic #Nicotine Delivery Systems, outlining latest research in this area & recommendations for regulating these products to protect #PublicHealth. @OncoAlert 👇🏼 ascopubs.org/doi/full/10.12…
account_circle
Utibe R. Essien, MD MPH(@UREssien) 's Twitter Profile Photo
Utibe R. Essien, MD MPH
done @UREssien

1 year ago

NEW in NEJM.

“Black and Hispanic persons were ⬇️ likely to receive bystander CPR at home (38.5%) than White persons (47.4%) and ⬇️ likely to receive bystander CPR in public locations than White persons (45.6% vs. 60.0%).“

This is a devastating finding.

nejm.org/doi/full/10.10…

NEW in @NEJM. “Black and Hispanic persons were ⬇️ likely to receive bystander CPR at home (38.5%) than White persons (47.4%) and ⬇️ likely to receive bystander CPR in public locations than White persons (45.6% vs. 60.0%).“ This is a devastating finding. nejm.org/doi/full/10.10…
account_circle